Skip to main content
. 2020 Jun 9;146(11):2979–2988. doi: 10.1007/s00432-020-03282-y

Table 2.

Characteristics of DRs and RECIST v1.1 defined PD without new lesions before and after PSM

Characteristics n (%) Before PSM After PSM
RECIST v1.1 defined PD without new lesions N = 84 DRs N = 52 p value RECIST v1.1 defined PD without new lesions N = 40 DRs N = 40 p value
Age [mean (SD)] 57.80 (10.11) 56.98 (11.10) 0.660 57.38 (10.93) 57.80 (10.77) 0.816
Sex
 Male 61 (72.6) 41 (78.8) 0.415 31 (77.5) 31 (77.5) 1.000
 Female 23 (27.4) 11 (21.2) 9 (22.5) 9 (22.5)
Histology
 Adenocarcinoma 38 (45.2) 31 (59.6) 0.257 20 (50.0) 23 (57.5) 0.598
 Squamous-cell carcinoma 36 (42.9) 17 (32.7) 13 (32.5) 13 (32.5)
 Other 10 (11.9) 4 (7.7) 7 (17.5) 4 (10.0)
Treatment
 PD-1 81 (96.4) 50 (96.2) 1.000 38 (95.0) 38 (95.0) 1.000
 PD-L1 3 (3.6) 2 (3.8) 2 (5.00) 2 (5.00)
Combined chemotherapy
 Yes 21 (25.0) 19 (36.5) 0.151 13 (32.5) 17 (42.5) 0.356
 No 63 (75.0) 33 (63.5) 27 (67.5) 23 (57.5)
Number of prior therapy
 0 7 (8.3) 19 (36.5) 0.000 7 (17.5) 7 (17.5) 1.000
 ≥ 1 77 (91.7) 33 (63.5) 33 (82.5) 33 (82.5)
PD-L1 expression [mean (SD)] 26.86 (24.98) 32.12 (25.39) 0.238 32.93 (27.48) 32.55 (26.06) 0.950
Stage
 III 8 (9.5) 6 (11.5) 0.707 5 (12.5) 5 (12.5) 1.000
 IV 76 (90.5) 46 (88.5) 35 (87.5) 35 (87.5)
Combined ICIs
 Yes 2 (2.4) 1 (1.9) 1.000 2 (5.0) 1 (2.5) 1.000
 No 82 (97.6) 51 (98.1) 38 (95.0) 39 (97.5)
Dosage of ICIs
 Standard 77 (91.7) 52 (100) 0.044 40 (100) 40 (100)
 Nonstandard 7 (8.3) 0 (0.00) 0 (0.00) 0 (0.00)